This observation suggests that although the combination of MDM2 inhibitors and topotecan is likely to provide more benefit for patients whose tumours are p53 functional, this combination treatment may not result in a lower efficacy in patients with p53 non-functional tumours. The gene discussed is MDM2; the disease is neoplasm.